When comparing TRAEs associated with anti-PD-1 monotherapy and anti-CTLA-4 monotherapy in melanoma patients, it becomes evident that the overall incidence of all-grade adverse effects is higher among anti-PD-1 patients. This evidence concerns the gene CTLA4 and melanoma.